Elucidating the specific pharmacological mechanism of action (MOA) of naturally developing compounds might be difficult. Whilst Tarselli et al. (sixty) developed the first de novo synthetic pathway to conolidine and showcased this naturally occurring compound correctly suppresses responses to each chemically induced and inflammation-derived pain, the pharmacologic target responsible https://www.proleviate.com/post/conolidine-an-alternative-natural-pain-relief-to-replace-traditional-painkillers